TYRVAYA Drug Patent Profile

Which patents cover Tyrvaya, and what generic alternatives are available?

Tyrvaya is a drug marketed by Oyster Point Pharma and is included in one NDA. There are ten patents protecting this drug and one Paragraph IV challenge.

This drug has forty-three patent family members in twenty countries.

The generic ingredient in TYRVAYA is varenicline tartrate. There are twelve drug master file entries for this compound. Thirty-two suppliers are listed for this compound. Additional details are available on the varenicline tartrate profile page.

DrugPatentWatch^® Litigation and Generic Entry Outlook for Tyrvaya

A generic version of TYRVAYA was approved as varenicline tartrate by PH HEALTH on August 11^th, 2021.

Summary for TYRVAYA

International Patents:	43
US Patents:	10
Applicants:	1
NDAs:	1
Patent Litigation and PTAB cases:	See patent lawsuits and PTAB cases for TYRVAYA

Paragraph IV (Patent) Challenges for TYRVAYA

Tradename	Dosage	Ingredient	Strength	NDA	ANDAs Submitted	Submissiondate
TYRVAYA	Nasal Spray	varenicline tartrate	0.03 mg/spray	213978	1	2023-04-21

US Patents and Regulatory Information for TYRVAYA

TYRVAYA is protected by ten US patents.

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Oyster Point Pharma	TYRVAYA	varenicline tartrate	SPRAY;NASAL	213978-001	Oct 15, 2021		RX	Yes	Yes	11,224,598
Oyster Point Pharma	TYRVAYA	varenicline tartrate	SPRAY;NASAL	213978-001	Oct 15, 2021		RX	Yes	Yes	11,903,943
Oyster Point Pharma	TYRVAYA	varenicline tartrate	SPRAY;NASAL	213978-001	Oct 15, 2021		RX	Yes	Yes	9,532,944
Oyster Point Pharma	TYRVAYA	varenicline tartrate	SPRAY;NASAL	213978-001	Oct 15, 2021		RX	Yes	Yes	11,903,941

International Patents for TYRVAYA

See the table below for patents covering TYRVAYA around the world.

Country	Patent Number	Title	Estimated Expiration
Portugal	3209295
Philippines	12017500602
European Patent Office	3209295
Spain	2986830

Supplementary Protection Certificates for TYRVAYA

Patent Number	Supplementary Protection Certificate	SPC Country	SPC Expiration	SPC Description
1044189	08C0039	France		PRODUCT NAME: VARENICLINE OU L?UN DE SES SELS PHARMACEUTIQUEMENT ACCEPTABLES, NOTAMMENT LE TARTRATE; REGISTRATION NO/DATE IN FRANCE: EU/1/06/360/001 DU 20060926; REGISTRATION NO/DATE AT EEC: EU/1/06/360/001 DU 20060926
1044189	SPC/GB08/034	United Kingdom		PRODUCT NAME: VARENICLINE, OPTIONALLY IN THE FORM OF A PHARMACEUTICALLY ACCEPTABLE SALT THEREOF, INCLUDING THE TARTRATE SALT; REGISTRATION NO/DATE: EU/1/06/360/001 - 010 20060928

Investment Scenario and Fundamentals Analysis for TYRVAYA (varenicline nasal spray)

Last updated: February 19, 2026

What is TYRVAYA and its market positioning?

TYRVAYA (varenicline nasal spray) is a prescription drug approved by the FDA in December 2022 for the treatment of allergic conjunctivitis. The medication offers a new formulation of an existing drug class used in allergy relief, aiming to improve symptom management with a non-invasive delivery method.

The drug is marketed by Sun Pharmaceutical Industries under license from Otonomy Inc., which developed the nasal spray.

Market Overview

Global Allergic Conjunctivitis Market

The global allergic conjunctivitis market is projected to grow from $1.5 billion in 2022 to approximately $2.1 billion by 2027 at a compound annual growth rate (CAGR) of 7%, driven by rising prevalence of allergy-related conditions and patient preferences for quick-acting treatments.

Key Competitors

• Olopatadine (Alcon, Regeneron)
• Ketotifen (various OTC brands)
• Azelastine (Allergic Rhinitis formulations)
• Emerging therapies including immunotherapies and novel formulations

Commercial Landscape

TYRVAYA positions itself as a convenient alternative to eye drops, targeting patients seeking quick, needle-free relief. Its nasal route aims to improve compliance, especially among those who dislike eye drops or have compliance issues.

Clinical and Regulatory Fundamentals

Efficacy

• Demonstrated significant reduction in allergy symptoms within 15 minutes post-administration in clinical trials
• Statistically superior symptom control versus placebo
• Minimal systemic absorption minimizes systemic side effects

Safety Profile

• Common adverse events include nasal discomfort and taste disturbances
• No significant cardiovascular risks identified
• No major safety concerns reported, supporting a favorable risk-benefit profile

Regulatory Status

• Approved by FDA in December 2022
• Pending regulatory submissions in Europe and other regions
• Data from Phase 3 trials submitted with OTC potential under review

Financial and Investment Fundamentals

Revenue Potential

• Initial launch targets allergy clinics, ENT specialists, and primary care
• Expected penetration rate: 15-20% within 2 years post-launch
• Price point: Approximately $70-80 per unit, comparable to topicals

Cost Structure and Profitability

• Manufacturing costs estimated at 20-25% of retail price
• Marketing and sales expenses projected at 25-30% of revenues
• Break-even anticipated after capturing 10-15% market share, within 3 years

Risks and Challenges

• Competition with established eye drop therapies with lower pricing
• Limited data on long-term safety, which may influence prescribing behavior
• Distribution constraints due to nasal spray handling and storage needs

Investment Considerations

Pros

• First-in-class nasal delivery for allergic conjunctivitis
• Clinical data indicates rapid onset and effective symptom control
• FDA approval reduces regulatory risk

Cons

• Competition from generic eye drops with entrenched market positions
• Market acceptance uncertain until real-world efficacy data emerges
• Pricing and reimbursement environment may pressure margins

Outlook and Valuation

• Market entry will likely take until mid-2024, with revenue ramp-up anticipated by 2025
• Potential for market share gain if physician and patient acceptance solidifies
• Valuation depends on sales trajectory, competitive response, and regulatory developments elsewhere

Key Takeaways

• TYRVAYA is a novel nasal spray for allergic conjunctivitis with rapid symptom relief.
• Regulatory approval mitigates development risk but competitive challenges remain.
• Financial prospects depend on market penetration, pricing, and reimbursement policies.
• Early-stage investments should consider market size, competitive dynamics, and product acceptance timelines.

Frequently Asked Questions

1. How does TYRVAYA compare with existing allergy treatments?
It offers faster symptom relief than traditional eye drops and avoids administration discomfort, potentially improving patient compliance.

2. What are the key regulatory risks?
While FDA approval reduces the regulatory hurdle in the U.S., approval delays or rejections in other markets could limit global rollout.

3. When will TYRVAYA start generating significant revenue?
Initial revenues are expected in late 2023 to early 2024, with growth contingent on prescriber acceptance and patient uptake.

4. What are the major competitive threats?
Entrenched brands like olopatadine and OTC antihistamines can leverage lower prices, challenging TYRVAYA’s market share.

5. Are there long-term safety concerns?
Current studies show a favorable safety profile, but ongoing post-marketing surveillance will clarify long-term safety.

References

1. MarketWatch. (2023). Global allergic conjunctivitis market forecast. https://www.marketwatch.com
2. FDA. (2022). TYRVAYA approval statement. https://www.fda.gov
3. Sun Pharmaceutical Industries. (2023). TYRVAYA product overview. https://www.sunpharma.com
4. Otonomy Inc. (2023). Clinical trial data and development pipeline. https://www.otonomy.com